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Background: Considerable proportion of patients does not respond to the cardiac resynchronization therapy (CRT).
This study investigated clinical relevance of left ventricular electrode local electrogram delay from the beginning of
QRS (QLV). We hypothesized that longer QLV indicating more optimal lead placement in the late activated regions
is associated with the higher probability of positive CRT response.
Methods: We conducted a retrospective, single–centre analysis of 161 consecutive patients with heart failure and
LBBB or nonspecific intraventricular conduction delay (IVCD) treated with CRT. We routinely intend to implant the
LV lead in a region with long QLV. Clinical response to CRT, left ventricular (LV) reverse remodelling (i.e. decrease in
LV end-systolic diameter - LVESD ≥10%) and reduction in plasma level of NT-proBNP >30% at 12-month post-
implant were the study endpoints. We analyzed association between pre-implant variables and the study endpoints.
Results: Clinical CRT response rate reached 58%, 84% and 92% in the lowest (≤105 ms), middle (106-130 ms) and
the highest (>130 ms) QLV tertile (p< 0.0001), respectively. Longer QRS duration (p = 0.002), smaller LVESD and a
non-ischemic cardiomyopathy (both p = 0.02) were also univariately associated with positive clinical CRT response.
In a multivariate analysis, QLV remained the strongest predictor of clinical CRT response (p< 0.00001), followed by
LVESD (p = 0.01) and etiology of LV dysfunction (p = 0.04). Comparable predictive power of QLV for LV reverse
remodelling and NT-proBNP response rates was observed.
Conclusion: LV lead position assessed by duration of the QLV interval was found the strongest independent
predictor of beneficial clinical response to CRT.
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Cardiac resynchronization therapy (CRT) has become an
established treatment strategy in patients with advanced
chronic systolic heart failure and a wide QRS complex.
There is an overwhelming evidence suggesting that CRT
improves exercise tolerance and the quality of life, pre-
vents hospitalizations for heart failure and has a* Correspondence: rospo@volny.cz
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reproduction in any medium, provided the orfavorable impact on prognosis [1–5]. Unfortunately, ap-
proximately 30% of patients fail to respond clinically to
CRT [6]. This figure is even higher when LV reverse re-
modelling is chosen as an endpoint for the response [6].
The possible reasons for non-responsiveness to CRT
include the amount of nonviable myocardium [7,8], nat-
ural progression of the underlying disease and a type
of the left ventricular (LV) conduction abnormality –
i.e. right bundle branch block (RBBB) [9–11]. In
addition, response to CRT seems to depend on the LVLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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were found predictive of a poor outcome [12].
As CRT aims principally to correct electrical ventricu-
lar dyssynchrony, optimal position of the LV lead could
be expected in the LV region with the most delayed
spontaneous depolarization. Based on our previous map-
ping studies in patients with LBBB [13], such regions are
predominantly located at the lateral wall, close to the
base of the heart. To insert the LV lead as close as pos-
sible to the latest activated region, we measured the QLV
defined as an interval between the beginning of the QRS
complex and the LV electrode local electrogram. During
implantation, the QLV interval was maximized whenever
possible. We hypothesized that the longer QLV will be
associated with the higher probability of resynchroniza-
tion and positive CRT response.
Methods
Patient population
We retrospectively analyzed data of all patients with
implanted biventricular pacemaker or defibrillator at the
Liberec Regional Hospital, Czech Republic between June
2005 and June 2010. CRT was indicated according to the
guidelines of the European Society of Cardiology [14]. In
this period, standardized echocardiographic examination
and biochemical assessment of heart failure were routine
parts of preimplant and one-year postimplant check-ups
at our institution. Only patients with LBBB or IVCD
were evaluated.
A total of 214 non-RBBB patients were implanted with
the CRT system within the above-mentioned period.
After analysis of all available data, 53 subjects were
excluded from the study. The exclusion criteria were as
follows: 1) death from other cause than heart failure dur-
ing the first 12 months of the follow-up (n = 6), 2) insuf-
ficient electrophysiological data from the implant
procedure (n = 35), 3) significant change in post-implant-
ation clinical status (e.g. coronary revascularization or
acute myocardial infarction) (n = 7), 4) unavailability of a
patient for follow-up (n = 2), 5) ventricular non capture
(n = 3).
All patients signed an informed consent with the pro-
cedure. The study was performed in accordance with
the guidelines proposed in the Declaration of Helsinki
and the analysis was approved by Ethics Committee of
the Regional Hospital in Liberec, reference number EK/
158/2011.
Implant procedure
Commercially available CRT systems were implanted by
two operators. The right ventricular lead was commonly
placed in the midseptum region. The LV lead was
inserted transvenously with a preference for lateral car-
diac veins, followed by posterolateral or anterolateralposition. Whenever possible, attempts were made to
maximize QLV interval at implant, i.e. when the LV lead
electrogram was not recorded in the terminal part of the
QRS, other available veins were explored in order to
achieve the longer QLV. In cases when the QLV interval
was significantly longer in a proximal part of a vein, all
efforts were made to provide stability of the lead in this
position (sometimes changing the lead design).
Empiric atrioventricular delay of 120 ms and V-V delay
0 ms were programmed at implant and were not rou-
tinely optimized. When no clinical improvement was
observed during early follow- up visit, at least one echo-
cardiographic-guided optimization of these intervals was
performed.
Electrophysiological measurements
The QLV interval was measured from the beginning of
the native QRS complex to the first sharp spike of LV
electrogram (Figure 1). After the final position of the left
ventricular lead was reached, the local bipolar electro-
gram from the tip of the LV lead was displayed simultan-
eously with a surface ECG at sweep speed of 200 mm/s
on the electrophysiological recording system (Biotronik
EP Control, Germany). QLV was measured by technician
using an electronic caliper. The recordings were carefully
visually inspected and manually edited, when necessary,
by a single observer (dedicated physician). Print outs of
all patients were archived. The QLV ratio, defined as
QLV divided by QRS duration (QRSd), was also assessed.
Echocardiographic examination
LV end systolic diameter (LVESD), LV end diastolic
diameter (LVEDD) measured in M-mode and LV ejec-
tion fraction (LVEF) assessed by planimetry were col-
lected at baseline and 12-month later using scanners of
one manufacturer (Philips, Amsterdam, The Nether-
lands). Measurements were performed according to the
recommendations of American Society of Echocardiog-
raphy [15] by one operator who was blinded to the QLV
values. A relative LVESD reduction of ≥10% was consid-
ered clinically significant.
Biomarker assessment
Plasma levels of N-terminal pro-hormone of brain natri-
uretic peptide (NT-proBNP) were assessed before implant
and at 12-month follow-up using commercially available
assay (Roche, Switzerland). A clinically meaningful decrease
of >30% was considered significant. In 24 patients NT-
proBNP datasets were not available.
Study objectives
The primary endpoint of the study comprised positive clin-
ical response to CRT at 12 months defined as an improve-
ment of the functional status by at least 1 NYHA class and/
Figure 1 Measurement of the QLV. Printout of the electrophysiological recording system at 200 mm/s paper speed showing the interval from
the beginning of the native QRS complex to the local electrogram from the LV lead. Labels: Lead II, III, aVR of the surface ECG; RVA-1/2 - right
ventricular electrogram; LV-1/2 - LV electrogram; HRA 1/2 - right atrial electrogram.
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Patients who died of heart failure within one year after im-
plantation were considered non-responders. Signs of LV re-
verse remodelling alone and NT-proBNP response were the
other endpoints of the study.
Statistical analysis
Continuous variables were expressed after testing for
normality of distribution (Shapiro Wilk’s test) as the
means with standard deviations and compared with the
2-tailed t-test for dependent or independent samples, as
appropriate. Non-normally distributed variables were
expressed as medians and interquartile range and com-
pared by Mann–Whitney U test or Wilcoxon’s paired
test, as appropriate. Categorical variables were expressed
as percentages and compared by χ2-test. Relationshipbetween variables (or their change) was assessed by Pear-
son’s correlation analysis. ANOVA with Scheffe’s post
hoc test was used for the analysis of CRT response rate
in subgroups defined by tertiles of individual baseline
variables. Multivariate regression analysis that included
all univariately significant factors was used to test the as-
sociation of CRT response rate with baseline clinical,
echocardiographic, and electrophysiological variables. A
p-value <0.05 was considered significant. All analyses
were performed using the STATISTICA vers. 6.1 soft-
ware (Statsoft, Inc.).
Results
The baseline characteristics of the study population are
shown in Table 1. During 12 months of follow-up, 3
patients died due to progressive heart failure and were
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(77.0%) and 37 (23.0%) patients were classified as clinical
responders and non-responders, respectively. There were
94 (58.4%) LV remodelling responders and 89/137
(65.0%) NT-proBNP responders.
Only exceptionally (n = 4), responders were identified
by LV remodelling alone, i.e. without improvement in
NYHA class. Baseline differences between responders
and non-responders are shown in Table 2. Responders
presented more frequently with non-ischemic cardiomy-
opathy, had less dilated left ventricle and wider QRS
complex. The greatest difference at implant was
observed both for the QLV interval and QLV ratio
(123 ± 26 ms vs. 98 ± 27 ms, and 0.76 ± 0.11 vs.
0.66 ± 0.14, respectively, both p< 0.00001). At 12-month
follow-up, responders differed significantly from non-
responders in NYHA class, LVEF, LV diameters, QRS
duration and NT-proBNP level. The QLV correlated
weakly but significantly with an increase in LVEF,Table 1 Baseline characteristics (n = 161)
Age (years) 67.0 ± 9.4 (32 – 86)
Female (%) 20.5
Ischemic cardiomyopathy (%) 53.4
NYHA functional class 3.1 ± 0.5 (2 – 4)
- NYHA II (%) 8.1
- NYHA III (%) 70.8
- NYHA IV (%) 21.1
LVEF (%) 24.7 ± 5.1 (15 – 35)
LVESD (mm) 57.1 ± 8.2 (37 – 90)
LVEDD (mm) 66.4 ± 7.6 (45 – 96)
Mitral regurgitation (grade) 1.9 ± 1.1 (1 – 4)
NT-proBNP (pg/ml) 4221 ± 5563 (270 – 35000)
Atrial fibrillation (%) 14.3
ICD (%) 67.1
QRSd (ms) 157 ± 20 (120 – 211)
QLV (ms) 117 ± 28 (65 – 189)
QLV ratio 0.74 ± 0.12 (0.46 – 0.95)
Baseline medication
- Beta-blockers (%) 96
- ACEI or ARB (%) 99
- Loop diuretics (%) 91
- Aldosterone antagonists (%) 89
The values are mean± standard deviation (range) or proportions. NYHA=New
York Heart Association; LVEF = left ventricular ejection fraction; LVESD = left
ventricular end-systolic diameter; LVEDD= left ventricular end-diastolic
diameter; NT-proBNP =N-terminal prohormone of brain natriuretic peptide;
QRSd =QRS complex duration; QLV = left ventricular electrode local
electrogram delay from the beginning of QRS; QLV ratio was calculated as
QLV/QRSd; ICD= implantable cardioverter-defibrillator; ACEI = angiotensin-
converting enzyme inhibitor; ARB = angiotensin receptor blocker.decrease in LVESD, shortening of QRSd and reduction
of NT-proBNP induced by CRT (Figure 2).
Among the baseline categorical variables, only ischemic
etiology of cardiomyopathy was significantly associated
with lower clinical CRT response rate (69.8 vs. 85.3%,
p = 0.02) and with less reverse LV remodelling (48.8 vs.
69.3%, p = 0.008) as compared with non-ischemic cardio-
myopathy. When continuous baseline variables were
categorized by tertiles (middle tertile cut-off points for
the QLV, QLV ratio, QRSd and LVESD were 105 -
130 ms, 0.694 - 0.806, 145 - 167 ms, and 55 - 60 mm, re-
spectively), significant association with clinical CRT re-
sponse was found for the baseline QLV (p= 0.00005),
QLV ratio (p = 0.0002), baseline QRSd (p = 0.002), and
LVESD (p = 0.02). Similarly, significant association with
reverse LV remodelling was found for the baseline QLV
(p = 0.00001) and QLV ratio (p = 0.00007), baseline QRSd
(p = 0.007), and LVESD (p= 0.004). Response rates in in-
dividual subgroups and their comparison are shown in
Figure 3. NT-proBNP response rates were 49% vs. 85%
(p = 0.002) in lower vs. upper tertile of QLV, respectively.
Other baseline factors (age, gender, basic heart rhythm,
LVEF, NYHA class, grade of mitral regurgitation and NT-
proBNP level) were not significantly (p> 0.20) associated
with clinical CRT response and were not subjected to
multivariate analysis.
Table 3 shows detailed results of univariate and multi-
variate association between baseline factors (analyzed as
continuous variables) and clinical CRT response, LV re-
modelling and NT-proBNP response. Because of inter-
dependence, the QLV and QLV ratio were entered
separately into the two linear regression models. Simi-
larly, because of the strong interaction between LVESD
and LVEDD, only LVESD, which was more tightly asso-
ciated with study endpoints, entered into both models.
When a stepwise forward analysis was applied, the QLV
and QLV ratio were comparably the most powerful and
independent predictors of study endpoints. LVESD and
etiology of cardiomyopathy appeared to be weaker but
still significant covariates. NT-proBNP response was
generally less predictable by baseline characteristics but
again the QLV and QLV ratio remained the strongest in-
dependent factors. When multivariate analysis was per-
formed separately in ischemic and non ischemic
subpopulations, the association between the QLV and
CRT effects was preserved in both subgroups.
A mutual combination of the QLV, LVESD, and QRSd
was used for further stratification of CRT effects. Patients
who belonged either to the “high-risk” tertiles of QLV ≤
105 ms and/or LVESD> 60 mm presented with lower
CRT response rate of 64% (n = 80). Among them, 47
patients had ischemic cardiomyopathy and had even
lower response rate of 57%. In a complementary subpo-
pulation, i.e. in those with both QLV> 105 ms and






Age (years) 66.7 ± 9.1 67.9 ± 10.5 0.51
Female (%) 21.8 16.2 0.46
Ischemic cardiomyopathy (%) 48.4 70.3 0.02
Atrial fibrillation (%) 13.6 16.2 0.70
NYHA class 3.1 ± 0.5median 3 (IQR 3–3) 3.2 ± 0.6median 3 (IQR 3–4) 0.52
Baseline LVEF (%) 24.9 ± 5.1median 25 (IQR 20–30) 23.8 ± 5.3median 23 (IQR 20–30) 0.27
LVESD (mm) 56.3 ± 8.2 60.1 ± 7.6 0.02
LVEDD (mm) 65.7 ± 7.6 68.7 ± 7.0 0.04
Mitral regurgitation grade 1.9 ± 1.1median 2 (IQR 1–3) 1.9 ± 1.1median 2 (IQR 1–3) 0.95
NT-proBNP (pg/ml) 4284 ± 5862median 2492 (IQR 1535–4800) 4002 ± 4444median 2700 (IQR 1898–4758) 0.57
QRSd (ms) 160 ± 20 147 ± 19 0.0006
QLV (ms) 122.8 ± 25.7 98.2 ± 27.0 0.000002
QLV ratio 0.76 ± 0.11 0.66 ± 0.14 0.000007
The values are mean± standard deviation, median (IQR, interquartile range) or proportions. Abbreviations as in Table 1.
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(n = 81). Among them, 41 patients had non-ischemic car-
diomyopathy and had even greater CRT response of 98%.
On the other hand, CRT response rate was only 52% in
patients with both QLV ≤ 105 ms and LVESD> 60 mm
(n= 23). Among them, 14 patients had ischemic cardio-
myopathy and even lower response rate (36%).Figure 2 Relationship of the QLV and CRT effects. The greater QLV at im
in LVESD, shortening of QRSd, and reduction in NT-proBNP at 12-month fo
provided. Abbreviations as in Table 1.Discussion
This study represents another piece of evidence on as-
sociation between response to CRT and the LV lead
position, expressed as the QLV interval. Patients in the
lowest QLV tertile (QLV ≤ 105 ms) had significantly
lower probability to become clinical responders or to
show LV reverse remodelling at 12-month follow-up.plantation of CRT system correlates with an increase in LVEF, decrease
llow-up. Pearsons’s correlation coefficients (r) with p-values are
Figure 3 CRT responder rates in subgroups defined by tertiles of baseline variables. Response rates in percentages when population was
categorized by tertiles of the QLV, QLV ratio, QRSd, and LVESD. Grey bars indicate clinical response to CRT and black bars proportion of patients
who showed reverse LV remodelling. Abbreviations as in Table 1.
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(92% of subjects) was observed in patients with both
QLV> 105 ms and LVESD ≤ 60 mm. Clinical relevance
of the QLV interval was further confirmed by its cor-
relation with the change in plasma levels of biochem-
ical marker of heart failure. All these findings support
the hypothesis that pacing within the late activated LV
region has the highest potential to correct electrical
dyssynchrony and associated LV mechanical dysfunc-
tion in patients with intraventricular conduction abnor-
mality of the LBBB type.
Comparison with other studies
Similar to our study, Singh et al [16]. analyzed clinical
response after one year of CRT in patients with LBBB
pattern. The authors found QLV/QRSD< 0.5 in signifi-
cant proportion of cases (27 of 71) and these subjects
presented with increased mortality and hospitalization
rate for heart failure. The proportion of such cases was
significantly lower (5 cases only, i.e. 3.1%) in our study.
This difference may reflect the fact that we attempted to
maximize QLV at implant and used wider spectrum of
LV lead designs to achieve this goal.
Our results are also in concordance with two other
recently published studies. The retrospective analysis by
Fatemi et al [17]. reported similar observation in a
smaller group of CRT patients (n = 72) with longer fol-
low-up (30 months). The authors found correlation ofthe QLV with LV reverse remodelling and/or clinical re-
sponse. The other study [18] was derived from the mul-
ticenter SMART AV Trial comparing different methods
of atrioventricular delay optimization strategy among
CRT subjects. In a prospectively designed substudy, the
response to CRT was assessed in 426 patients with a
50% rate of reverse remodelling (change in LV end sys-
tolic volume) after 6 months of follow-up. Similar to
our results, higher proportion of reverse remodelling
was found in subjects with longer QLV. Based on their
results, the authors recommended for positioning the
LV lead to reach the QLV at least 95 ms. However,
there are some important differences between our trial
and the two aforementioned studies that have to be
emphasized. First, the patient populations differed sub-
stantially. In both other studies, patients with RBBB
were enrolled. In the study by Fatemi et al., patients
with scar in the lateral wall were excluded. In SMART
AV, there was a higher proportion of women (34 vs.
20% in our study) and fewer patients were in NYHA IV
(3 vs. 20%). The follow-up in SMART AV Trial was sig-
nificantly shorter (6 months versus 12 months). Second,
none of the other studies attempted to maximize the
QLV already at implant.
In contrast to the two above mentioned trials [17,18]
and contrary to general expectation, we observed higher
proportion of clinical responders and LV reverse remod-
elling in our CRT population. One plausible explanation
Table 3 Univariate and multivariate association between baseline factors and clinical, echocardiographic and
biochemical CRT response





















ICM/NICM 0.02 0.008 0.04 0.04 0.01 Ns 0.046 0.02 ns
QLV <0.00001 <0.00001 0.0001 <0.00001 <0.00001 0.0001 - - -
QLV ratio <0.00001 <0.00001 0.001 - - - 0.0004 <0.00001 0.01
QRSd 0.0005 0.002 0.003 ns ns Ns 0.04 ns 0.04
LVESD 0.01 0.0006 0.12 0.009 0.0002 Ns 0.01 0.0003 ns
LVEDD 0.03 0.0007 0.19 - - - - - -
The figures are p-values for linear regression between baseline variables and CRT response rates analyzed in two multivariate models that included either QLV
(Model 1) or QLV ratio (Model 2). ICM – ischemic cardiomyopathy; NICM – non-ischemic cardiomyopathy. Other abbreviations as in Table 1.
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to have less benefit from CRT [9–11] from our study.
Another reason, at least in comparison with the SMART
AV Trial, could be the longer follow-up in our study that
might allow reverse remodelling in more patients. The
third possible explanation, which seems to be the most
important, is our strategy to place the LV lead at the site
with the latest possible activation. This practice reflects
our earlier experience with electroanatomic mapping of
late activated regions and resulted in longer median QLV
interval in our cohort (116 ms) and narrower interquar-
tile range (IQR) of 40 ms (95-135 ms) in contrast to the
SMART AV study with median QLV of 95 ms and IQR
of 50 ms (70-120 ms). Preserved predictive power of the
QLV even after a priori optimization resulting in nar-
rower range of QLV further underlines its clinical utility.
It also has to be emphasized that the method of QLV
measurement differed in both studies. In SMART AV
substudy [18], measurements were performed from the
device programmers using a sweep speed of 100 mm/s.
This strategy required correction for the average variable
latency (or noise) between the alignment of surface ECG
and the electrogram channels in these devices. In con-
trast, our measurements were performed using electro-
physiological recording system with a simultaneous
display of LV electrograms and surface ECG channels at
200 mm/s sweep speed.
Study implications
We acknowledge that to dichotomize the effect of CRT
responder vs. non-responder is an oversimplification.
The response to CRT is a continuum with patients who
worsen on one side and hyper-responders on the other.
However, significant correlation between the QLV and
LV reverse remodelling suggests that achieving higher
QLV value at implant means not only higher likelihood
of a positive clinical and echocardiographic response to
CRT but also the greater magnitude of the effect. Thus,
our results clearly imply that the QLV should bemaximized during the LV lead implant as much as pos-
sible. On the contrary, patients with QLV ≤ 105 ms are
less likely to show positive response to CRT.
We also assessed predictive power of another param-
eter, QLV ratio that related the QLV to QRSd. The pre-
diction characteristics of QLV ratio for response to CRT
appeared somewhat inferior to the QLV interval. Obvi-
ously, this is because the QLV interval conveys not only
information on the optimal lead position but also reflects
the QRSd that is univarite predictor of CRT response per
se. Such composite predictor has to be inherently better
than QLV ratio that describes LV lead positioning only.
Concordantly, QRSd became non-significant predictor of
CRT effects when entered the multivariate model to-
gether with the QLV interval. For practical reasons, guid-
ing the LV lead placement by readily available QLV
interval can be recommended. On the other hand, QLV
ratio (together with other clinical variables) rather than
QLV interval might be preferred for optimization of CRT
effects in future interventional CRT trials investigating al-
ternative methods of LV pacing.
Study limitations
This study has several limitations. First, it was a retro-
spective, single-center study and this may limit
generalization of its results. Second, LV lead positions
were not recorded routinely on cineloops and therefore,
we could not evaluate correlation between the QLV and
actual pacing site location. Third, the amount and the lo-
cation of LV scar tissue that may interfere with the CRT
response was not assessed and included in multivariate
analysis. Fourth, we assessed LV reverse remodelling
using one-dimensional parameter, specifically LVESD,
because LV end-systolic volume (LVESV) was not avail-
able in all patients. This might influence to some extent
the results on reverse remodelling as LVESV is more fre-
quently used for this purpose. On the other hand, our di-
chotomy of ≥10% for LVESD corresponds to ≥21-22%
for LVESV when estimated by Teichholz formula, i.e.
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more stringent than that used, for example, in SMART
AV substudy (≥15% for LVESV). The measurement of LV
end-systolic volume is also less reproducible as com-
pared with LVESD. Some studies have shown that inter-
(<20%) and intra-individual (5-10%) variability of LV
end-systolic volume is higher as compared with variabil-
ity of LVESD (1-3% intra-individually) [12]. Finally, be-
cause we did not find relevant dichotomy for clinically
significant NT-proBNP decrease in literature we arbitrar-
ily used the cut-off point of >30% and made sure that al-
ternative cut-off values provided comparable results.
Conclusions
LV lead position assessed by the QLV interval was found
the strongest independent predictor of beneficial re-
sponse to CRT, followed by LVESD and etiology of LV
dysfunction. In patients with long QLV (>130 ms), clin-
ical CRT response and LV remodelling rates at one year
after implant were higher by 58% and 124%, respectively,
when compared with short QLV ≤ 105 ms. This associ-
ation between the QLV and CRT effects was preserved
both in ischemic and non-ischemic cardiomyopathy sub-
groups. Therefore, attempts to maximize the QLV during
LV lead placement should be considered in all non-RBBB
CRT patients. Clinical utility of this approach should be
tested in prospective interventional trial.
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